Abstract:Abstract Objective To establish myelodysplastic syndrome cell line MUTZ-1 cell mice model. Methods 75 SCID mice and 10 BALB/CA-node mice were studied in this experiment. MDS-REBT cell line MUTZ-1 cells were cultured in vitro and 1 x108 /ml cell were subcutancously implanted in 4~6-week-old First-Generation SCID mice and BALB/CA-node mice respectively. The subcutancous tumor cells from First-Generation MDS-REBT cell line MUTZ1 cells mice model were respectively implanted in Second-Generation SCID mice and BALB/CA-node mice. The latent period and the rate of subcutancous tumor formation was observed, and tumor size was measured by the MTD twice a week. The biological characteristics of the subcutancous tumor cells were checked and evaluated by the methods of cell morphology and pathology and histopathology and immunology by flow cytometer, chromosome analysis and immunohistochemistry stain. It has been experimented tentatively that arsenic trioxide (AS2O3) (with 7.5mg/g mouse/d x 3d) was injected into abdominal cavity in 10 SCID mice to observe the drug effect on tumor formation in vivo. Results The rate of the subcutancous tumor formation was 98.6% (70/71)in SCID mice and 62.5%(5/8)in BALB/CA-nude micerespectively,(P=0.0027). The latent period of the subcutancous tumor formation were 10~17d (median 12d) in 61 SCID mice without injected arsenic trioxide and were 26~31d (median 29d) in 10 SCID mice with arsenic trioxide (with 7.5mg/g mouse/d x 3d) injected into abdominal cavity respectively. The latent period of the subcutancous tumor formation in the group of SCID mice injected by AS2O3 was significantly longer than that of non-injected by AS2O3(Z=5.339, P<0.001), which showed that AS2O3 has probably a inhibition effect on the subcutancous tumor growth of SCID mice model in vivo. The results showed the subcutancous tumor cells of mice model have the biological characteristics of a Hum-MDS-REBT cell line MUTZ1 cell and were anthropo- source. The metastases in liver were found 8 weeks after implanted. HE staining on paraffin sections showed that the tumor cells were microscopic observed on liver and spleen and kidney and medullary cavity of bone and skin. Immunohistochemistry staining showed the subcutancous tumor cells of the mice model have the overexpression of P53 protein, which cued that these tumor cells has the P53 mutation and showed human tumor propert. Conclusion A human myelodysplastic syndromes-REBT cell line MUTZ1 cell-severe combined immunodeficiency (SCID) mice model was successfully established, which could be used for the advanced investigation of drug experiment as an animal model system in vivo.

Establishment of Subcutaneous Xenograft Models of Human Multiple Myeloma in NOD/SCID Mice

[Establishment of xenotransplated mouse model using primary multiple myeloma cells].

[Establishment of Multiple Myeloma Mouse Models Expressing Brain Derived Neurotrophic Factor].

The Establishment of Mice Model with Myelodysplastic Syndrome Cell Line MUTZ-1 Cell.

[Establishment of Patient-Derived Xenotransplantation Models for Non-Small Cell Lung Cancer in Immune Deficient Mice].

Advances in Modeling of Multiple Myeloma in Mice

Development of Intraperitoneally Transplantated Human Ovarian Carcinoma Model with Immune Reconstruction in Severe Combined Immunodeficient Mice

In Vivo Induction of Malignant Transformation of Nude Mouse B Lymphocytes by a Human Multiple Myeloma.

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Establishment of an animal model of human myeloid leukemia in NOD/SCID mice with acute myeloid leukemia stem cells

Esablishment of Human Lung Cancer Model in the Scid Mouse

Establishment of NOD/SCID Mouse Models of Human Hepatocellular Carcinoma Via Subcutaneous Transplantation of Histologically Intact Tumor Tissue.

Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice

Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice

[Establishment of K562/NOD-SCID Mouse Model with Leukemia].

[Establishment of a NOD/SCID Mouse Model with Human Immune Reconstitution Bearing Human Triple-Negative Breast Cancer].

Establishment of a Balb/c-nu-hu model of human plasmacytoma

A Novel Animal Model for Bone Metastasis in Human Lung Cancer

Genetically Modified Myeloma Cell Vaccine Inducing Antitumor Immune Response in Vivo.

Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID β2mnull mice

Establishment of K562/NOD-SCID mouse model with leukemia]